Telephone monitoring of adverse events during an MF59^®-adjuvanted H5N1 influenza vaccination campaign in Taiwan

Figures & data

Table 1. Characteristics of 292 study participants

Characteristic	Number of participants	(%)
Sex
Male	108	(37)
Female	184	(63)
Age
18–59 y	266	(91)
≥60 y	26	(9)
Dose
First	202	(69)
Second	90	(31)
Received 2010–11 seasonal influenza vaccination
Yes	235	(80)
No	56	(19)
Unknown	1	(< 1)
ACIP high-risk conditions^a
Yes	42^b	(14)
No	250	(86)

ACIP, Advisory Committee on Immunization Practices. ^aConditions associated with increased risk for serious medical complications from influenza.^{4 b}Including cardiovascular (n = 10), chronic asthma or other pulmonary (n = 12), diabetes mellitus or other metabolic (n = 9), neuromuscular (n = 4), and hepatic (n = 10) disorders.

Figure 1. Solicited local and systemic reactions reported within 7 to 10 d after A/H5N1 vaccination. Classified by symptom after the first (white bars) or second (gray bars) vaccination in study participants.

Table 2. Factors associated with the occurrence of adverse events within 7 to 10 d of A/H5N1 vaccination

Variable	Number of participants	Number of patients with adverse events	Univariate OR (95% CI)	Multivariate OR^a (95% CI)
Sex
Male	98	46	Reference	Reference
Female	172	117	2.40 (1.40–4.13)	2.06 (1.18–3.63)
Age
18–59 y	247	156	3.90 (1.45–11.64)	3.08 (1.11–9.45)
≥60 y	23	7	Reference	Reference
Dose
First	186	124	2.30 (1.32–4.04)	2.16 (1.22–3.86)
Second	84	39	Reference	Reference
Received 2010–11 seasonal influenza vaccination
Yes	213	131	1.12 (0.59–2.09)	-
No	56	32	Reference	-
ACIP high-risk conditions
Yes	39	22	Reference	-
No	231	141	1.21 (0.57–2.53)	-

OR, odds ratio; CI, confidence interval; ACIP, Advisory Committee on Immunization Practices. ^aAdjusted for variables listed.

Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al, Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:RR-8 1 - 62; PMID: 20689501

 PubMedGoogle Scholar